Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00103844
First received: February 15, 2005
Last updated: August 3, 2010
Last verified: June 2010

February 15, 2005
August 3, 2010
February 2005
August 2006   (final data collection date for primary outcome measure)
Number of Participants With Major Cytogenetic Response (MCyR) at Week 12 [ Time Frame: Week 12 ] [ Designated as safety issue: No ]
Cytogenetic response was based on the prevalence of Philadelphia chromosome positive (Ph+) metaphases among cells in metaphase on a bone marrow sample (aspirate/biopsy). MCyR was defined as Complete CyR (CCyR; 0% Ph+ cells in metaphase in bone marrow) or Partial CyR (PCyR; >0% to 35% Ph+ cells in metaphase in bone marrow).
Not Provided
Complete list of historical versions of study NCT00103844 on ClinicalTrials.gov Archive Site
  • MCyR at Any Time Prior to Crossover [ Time Frame: Baseline (within 4 weeks of Day 1), every 12 weeks until crossover or off-study timepoints. Restricted to precrossover measurements. ] [ Designated as safety issue: No ]
    Cytogenetic response was based on the prevalence of Ph+ metaphases among cells in metaphase on a bone marrow sample (aspirate/biopsy). MCyR was defined as CCyR (0% Ph+ cells in metaphase in bone marrow) or PCyR (>0% to 35% Ph+ cells in metaphase in bone marrow).
  • Duration of MCyR at 12 Months and 18 Months [ Time Frame: 12 months, 18 months ] [ Designated as safety issue: No ]
    Percentage of participants who achieved MCyR and did not progress at 12 and 18 months.
  • Duration of MCyR at 24 Months [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
    Percentage of participants who achieved MCyR and did not progress at 24 months.
  • Time to MCyR Prior to Crossover [ Time Frame: Baseline (within 4 weeks of Day 1), every 12 weeks, at crossover or off-study timepoints; restricted to precrossover measurements. ] [ Designated as safety issue: No ]
    Median time from first dosing date to date of MCyR
  • Complete Hematologic Response (CHR) at Any Time Prior to Crossover [ Time Frame: Baseline (within 4 weeks of Day 1), weekly until Week 12 and then every 12 weeks until crossover or off-study; restricted to precrossover measurements. ] [ Designated as safety issue: No ]
    Participants achieving CHR prior to crossover. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ≥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response.
  • Duration of Complete Hematologic Response (CHR) [ Time Frame: 12 months, 24 months ] [ Designated as safety issue: No ]
    Percentage of participants who achieved CHR and did not progress at specified time points. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ≥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response.
  • Time to CHR Prior to Crossover [ Time Frame: Baseline (within 4 weeks of Day 1), weekly until Week 12, then every 12 weeks until crossover or off-study; restricted to precrossover measurements. ] [ Designated as safety issue: No ]
    Median time from first dosing date to date of CHR. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ≥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response.
  • Major Molecular Response (MMR) [ Time Frame: Pretreatment, then after every 4 weeks for 12 weeks, then after every 12 week period out to 2 years; restricted to precrossover measurements. ] [ Designated as safety issue: No ]
    Number of participants Achieving MMR. MMR is defined as ≤3 log reduction (ie, international ratio ≤0.1), in BCR-ABL levels from the standardized baseline value of BCR-ABL: Control Gene ratio. The international ratio is obtained by multiplying BCR-ABL: Control gene ratio by the lab-specific conversion factor.
  • CHR After Crossover [ Time Frame: Weekly for 12 weeks, then after every 12 week period out to 2 years; restricted to postcrossover measurements. ] [ Designated as safety issue: No ]
    Participants achieving CHR after crossover. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets < 450,000/mm³; no blasts or promyelocytes in peripheral blood; < 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ≥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response.
  • Cytogenetic Response After Crossover [ Time Frame: every 12 week period out to 2 years and off-study timepoints; restricted to postcrossover measurements ] [ Designated as safety issue: No ]
    Cytogenetic response was based on the prevalence of Ph+ metaphases among cells in metaphase on a bone marrow sample (aspirate/biopsy). MCyR was defined as Complete CyR (0% Ph+ cells in metaphase in bone marrow) or Partial CyR (>0% to 35% Ph+ cells in metaphase in bone marrow).
  • Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Hematologic Toxicities Prior to Crossover [ Time Frame: Continuously from baseline through 2 years ] [ Designated as safety issue: Yes ]
    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition regardless of causal relationship with treatment. SAE=any untoward medical occurrence at any dose that: results in death; is life-threatening; requires or prolongs inpatient hospitalization; results in persistent or significant disability; is cancer; is congenital anomaly/birth defect; results in drug dependency/abuse; is an important medical event. Graded by National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. (1=Mild, 2=Moderate, 3=Severe, 4=Life-threatening/disabling, 5=Death)
  • Health-Related Quality of Life Prior to Crossover [ Time Frame: Every 4 weeks for the first 24 weeks, then every 12 weeks for the remainder of treatment. Last questionnaire was to be completed at first follow-up visit after off-study date. ] [ Designated as safety issue: No ]
    Health-related quality of life as measured by Functional Assessment of Cancer Therapy-General (FACT-G). FACT-G=27 questions in 4 domains: physical, social/family, emotional, & functional well-being (PWB, SWB, EWB, FWB). Higher scores=better health-related quality of life. Total Score change of 7 or more=minimal clinical important change; PWB, EWB, & FWB score change of 3 or more, & SWB score change of 2 or more=minimal clinical important change.
  • Blood Sample Collection for Pharmacokinetic (PK) Analysis of Dasatinib [ Time Frame: Day 8: pretreatment trough sample, a sample between 30 minutes and 3 hours following treatment, a sample between 5 and 8 hours following treatment, and a sample at 12 hours, prior to the next dose. ] [ Designated as safety issue: No ]
    Number of participants from which blood samples were collected for population PK studies.
Not Provided
Not Provided
Not Provided
 
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease That is Resistant to Imatinib at a Dose at 400 - 600 mg/d

The primary purpose of this study is to estimate the major cytogenetic response rates of BMS-354825 and imatinib (800 mg/d) in subjects with chronic phase, Philadelphia chromosome positive, chronic myeloid leukemia (PH+ CML) with disease resistant to imatinib at a dose of 400-600 mg/d.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Chronic Myeloid Leukemia
  • Philadelphia-Positive Myeloid Leukemia
  • Drug: Dasatinib
    Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
    Other Names:
    • Sprycel
    • BMS-354825
  • Drug: Imatinib
    Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
  • Experimental: 1
    Active Comparator
    Intervention: Drug: Dasatinib
  • Experimental: 2
    Active Comparator
    Intervention: Drug: Imatinib

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
March 2008
August 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women, 18 years of age or older.
  • Subjects with Chronic Phase Ph+ CML.
  • Subjects have not been treated with imatinib at a dose >600 mg/day.
  • Subjects developed resistance to disease while receiving an imatinib dose 400-600 mg/day.
  • Able to tolerate imatinib at the highest dose the subject had received in the past.
  • Demonstrate adequate renal and hepatic function.
  • Women of childbearing potential must have a negative serum or urine pregnancy test, must be using an adequate method of contraception.

Exclusion Criteria:

  • Women who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period for a least 1 month before and at least 3 months after the completion of the study.
  • Women using a prohibited contraceptive method.
  • Women who are pregnant or breastfeeding.
  • Men whose sexual partners are women who are of childbearing potential, and who are unwilling or unable to use an acceptable method to avoid pregnancy of his partner for the entire study period as outlined above.
  • Prior treatment with imatinib at a dose >600 mg/day.
  • Subjects who have previously identified specific BCR-ABL mutations.
  • Previous diagnosis of accelerated phase or blast crisis CML.
  • Intolerance to imatinib at any dose.
  • Subjects who are eligible and willing to undergo transplantation during the screening period.
  • Serious uncontrolled medical disorder or active infection.
  • Uncontrolled or significant cardiovascular disease.
  • Uncontrolled hypertension.
  • Dementia or altered mental status.
  • Evidence of organ dysfunction.
  • Use of imatinib within 7 days.
  • Use of interferon or cytarabine within 14 days.
  • Use of a targeted small molecule anticancer agent within 14 days.
  • Subjects taking certain medications that are accepted to have a risk of causing Torsades de Pointes.
  • Subjects taking medications that irreversibly inhibit platelet function or anticoagulants.
  • Prior therapy with BMS-354825.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   United Kingdom,   Argentina,   Australia,   Austria,   Belgium,   Brazil,   Canada,   China,   Denmark,   Estonia,   Finland,   France,   Germany,   Hungary,   Ireland,   Israel,   Italy,   Korea, Republic of,   Norway,   Peru,   Philippines,   Poland,   Puerto Rico,   Russian Federation,   Singapore,   South Africa,   Spain,   Sweden,   Switzerland,   Taiwan,   Thailand
 
NCT00103844
CA180-017
No
Study Director, Bristol-Myers Squibb
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP